Topical cannabidiol - Futura Medical/CBDerma Technology
Alternative Names: CBD-100Latest Information Update: 28 Apr 2024
At a glance
- Originator CBDerma Technology; Futura Medical
- Developer Futura Medical
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in Pain in United Kingdom (Topical, Gel)
- 05 Mar 2020 Preclinical trials in Pain in United Kingdom (Topical) (Futura Medical pipeline, March 2020)
- 30 Jun 2019 Futura Medical and CBDerma Technology enter into a collaboration for the development of topical cannabidiol formulation